Genoptix Announces National Three-Year Agreement with Aetna





Genoptix, Inc. announced that it will participate in Aetna's (AET) national provider network to offer specialized laboratory and comprehensive diagnostic services designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma.

As a result, physicians will have additional choices for in-network specialty lab services for Aetna members. Aetna members could also benefit from lower out-of-pocket costs for Genoptix's laboratory services since copays, deductibles and coinsurance will be based on their in-network benefit levels and established rates for Genoptix's laboratory services.  The three-year agreement with Aetna, one of the nation's largest health benefits companies serving 19 million medical members, is effective April 1, 2010. Additional terms of the contract were not disclosed.

"We are excited to announce our contract with Aetna, a significant milestone for Genoptix," said Tina S. Nova, Ph.D., President and CEO of Genoptix.  "This relationship gives us the opportunity to make our specialized diagnostic services more accessible to Aetna's participating physicians and their patients across the country. We are proud to extend the benefits afforded by our offerings and our commitment to maintaining the highest standards in diagnostics for our physician customers."  

About Genoptix, Inc.

Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilizes sophisticated technology to provide integrated testing and actionable diagnostic reports.  Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma. Founded in 1999, Genoptix is traded on the Nasdaq Select Global Market and is a member of the S&P SmallCap 600 Index.  Genoptix is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com .